[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"polyglandular-autoimmune-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:polyglandular-autoimmune-syndrome":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100494317","treatment-study-in-patients-treated-with-both-insulin--hydrocortisone-100494317",false,"NCT05716607","Treatment Study in Patients Treated With Both Insulin & Hydrocortisone","Randomized Cross-over Trial in Patients Treated With Both Insulin & Hydrocortisone","INSCORT","Inclusion Criteria:\n\nMen and women at age 18 to 70 years, with BMI 18-32 kg\u002Fm2 and well-defined both insulin-treated diabetes \\& Addison's disease for \\>12 months each, on insulin treatment and stable hydrocortisone replacement with once-daily dual-release hydrocortisone (20-30 mg\u002Fday) for \\>3 months.\n\nExclusion Criteria:\n\n* Any medication with other glucose lowering agents than insulin\n* Any additional underlying or intercurrent disease that may need regular or periodic pharmacological treatment with glucocorticoids during the study period, including infectious diseases\n* Any medication with agents which in the investigator's judgement might interfere with the study drugs kinetics, including therapies affecting gastrointestinal emptying or motility\n* Any medication with oral estrogen supplementation and\u002For regular DHEA medication for the past 4 weeks\n* Clinically significant renal dysfunction with a serum creatinine above 160 mmol\u002FL\n* Active malignancy\n* Clinical or laboratory signs of significant cerebral, cardiovascular, respiratory, hepatobiliary\u002Fpancreatic disease which in the investigator's judgement may interfere with the study assessment\n* Pregnant or lactating women\n* Alcohol\u002Fdrug abuse or any other condition associated with poor patient compliance, including expected non-cooperation, as judged by the investigator.","ALL","18 Years","70 Years",{"count":21,"type":22},16,"ESTIMATED","INTERVENTIONAL",[25],"NA","The aim of INS.CORT trial is, by studying glycemic variability in a well-defined patient group with both insulin \\& hydrocortisone (patients with concomitant insulin-treated diabetes \\& Addison's disease) and collecting information about the administration -time point and doses- of insulin, hydrocortisone and food intake with the help of new technology to improve the treatment in all patients treated with both insulin \\& glucocorticoids.",[28,29,30],"Diabetes Mellitus","Adrenal Insufficiency","Polyglandular Autoimmune Syndrome",[32,33,34,35],"Insulin treatment","Hydrocortisone treatment","Opposing effects on glucose metabolism","Randomized Controlled Trial","NOT_YET_RECRUITING","2024-04-28",{"date":39,"type":40},"2024-04-30","ACTUAL",{"date":42,"type":22},"2024-09",{"date":44,"type":22},"2027-12",{"name":46,"class":47},"Vastra Gotaland Region","OTHER_GOV"]